Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Check out our MDGL stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Review the current Madrigal Pharmaceuticals Inc (MDGL:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MDGL is the best investment for you.

The USDA considers vaccinating poultry for bird flu, while the EU supports Madrigal's liver drug Rezdiffra. Meanwhile, the ...

The USDA is considering vaccinating poultry against bird flu, potentially influencing exports while causing significant ...

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...